论文部分内容阅读
探讨上腔静脉内支架（ｓｔｅｎｔ）置入治疗原发性肺癌合并上腔静脉梗阻（ＳＶＣＯ）的临床疗效。方法采用经皮穿刺股静脉插管的方法对５例肺癌合并上腔静脉梗阻的患者分别向狭窄上腔静脉置入一枚直径１０ｍｍ或１４ｍｍ，长６０ｍｍ或７０ｍｍ的镍钛记忆合金支架。结果全部患者支架置入一次成功，上腔静脉血流恢复通畅。４例患者ＳＶＣＯ症状很快消除。其中２例患者成活４月和２０月，无复发；２例患者术后４月和５月因肺癌死亡时ＳＶＣＯ亦无复发。１例患者术后短期内复发，经溶栓治疗后症状明显改善。结论血管内支架治疗肺癌合并ＳＶＣＯ是一种有效的姑息治疗方法。为了延长这类患者的生存期，必须重视原发性肺癌的治疗
To investigate the clinical efficacy of stent placement in the treatment of primary lung cancer with superior vena cava obstruction (SVCO). Methods Five patients with lung cancer and superior vena cava obstruction were treated by percutaneous puncture of the femoral vein to insert a nickel-titanium shape memory alloy stent with a diameter of 10 mm or 14 mm and a length of 60 mm or 70 mm in the superior vena cava. Results All patients were successfully placed in the stent and the blood flow of the superior vena cava was restored. SVCO symptoms quickly resolved in 4 patients. Two of these patients survived in April and 20 months without recurrence; 2 patients also had no recurrence of SVCO when they died of lung cancer at 4 months and 5 months after surgery. One patient had a short-term recurrence after surgery and the symptoms improved significantly after thrombolysis. Conclusion Intravascular stenting for lung cancer with SVCO is an effective palliative treatment. In order to prolong the survival of these patients, we must pay attention to the treatment of primary lung cancer.